Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Genetics

Topic: Brain proteins, microglia and lab models

Plain-language summary

Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in cerebrospinal fluid (CSF) has been associated with Alzheimer's disease (AD). TREM2 plays a critical role in microglial activation, survival, and phagocytosis; however, the pathophysiological role of sTREM2 in AD is not well understood. Understanding the role of sTREM2 in AD may reveal new pathological mechanisms and lead to the identification of therapeutic targets. We performed a genome-wide association study (GWAS) to identify genetic modifiers of CSF sTREM2 obtained from the Alzheimer's Disease Neuroimaging Initiative. Common variants in the membrane-spanning 4-domains subfamily A ( MS4A ) gene region were associated with CSF sTREM2 concentrations (rs1582763; P = 1.15 × 10 -15 ); this was replicated in independent datasets. The variants associated with increased CSF sTREM2 concentrations were associated with reduced AD risk and delayed age at onset of disease. The single-nucleotide polymorphism rs1582763 modified expression of the MS4A4A and MS4A6A genes in multiple tissues, suggesting that one or both of these genes are important for modulating sTREM2 production. Using human macrophages as a proxy for microglia, we found that MS4A4A and TREM2 colocalized on lipid rafts at the plasma membrane, that sTREM2 increased with MS4A4A overexpression, and that silencing of MS4A4A reduced sTREM2 production. These genetic, molecular, and cellular findings suggest that MS4A4A modulates sTREM2. These findings also provide a mechanistic explanation for the original GWAS signal in the MS4A locus for AD risk and indicate that TREM2 may be involved in AD pathogenesis not only in TREM2 risk-variant carriers but also in those with sporadic disease.

What this study adds

Evidence grade: Low

The variants that raised soluble TREM2 were associated with lower Alzheimer's risk and later onset, but the record gives no size for either effect. In human macrophages, used as a stand-in for brain immune cells, turning MS4A4A up raised soluble TREM2 and silencing it lowered it, which the authors say "suggest[s] that MS4A4A modulates sTREM2".

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Deming, Y., Filipello, F., Cignarella, F., Cantoni, C., Hsu, S., Mikesell, R., et al. (2019). The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Science translational medicine. https://doi.org/10.1126/scitranslmed.aau2291

Vancouver

Deming Y, Filipello F, Cignarella F, Cantoni C, Hsu S, Mikesell R, et al. The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Science translational medicine. 2019. doi:10.1126/scitranslmed.aau2291. PMID: 31413141.

BibTeX

@article{deming2019-31413141,
  author  = {Deming, Y. and Filipello, F. and Cignarella, F. and Cantoni, C. and Hsu, S. and Mikesell, R. and Li, Z. and Del-Aguila, J. L. and others},
  title   = {{The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk}},
  journal = {Science translational medicine},
  year    = {2019},
  doi     = {10.1126/scitranslmed.aau2291},
  pmid    = {31413141},
  url     = {https://doi.org/10.1126/scitranslmed.aau2291}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In a genome-wide study of spinal-fluid samples from the Alzheimer's Disease Neuroimaging Initiative, common variants in the MS4A gene region were strongly linked to levels of soluble TREM2, a protein tied to the brain's immune cells (P = 1.15 × 10⁻¹⁵), and this was replicated in independent datasets. The variants that raised soluble TREM2 were associated with lower Alzheimer's risk and later onset, but the record gives no size for either effect. In human macrophages, used as a stand-in for brain immune cells, turning MS4A4A up raised soluble TREM2 and silencing it lowered it, which the authors say "suggest[s] that MS4A4A modulates sTREM2". No treatment was tested.

Study details

How this study scored 54/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 54 of 100.54 of 100 points earned46 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Science translational medicine)
Journal's citation record 3 / 4 Science Translational Medicine: journal h-index 365 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 273 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 30.3 citations a year over 9 year(s) since 2019
Impact for its field and year 4 / 6 Cited 11.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 43 other studies in this library
Still being cited 3 / 4 Cited 105 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Carlos C Cruchaga: h-index 102 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 23 institution(s) in 6 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 31413141)
Free to read 0 / 2 Behind a paywall — scores zero
Total 54 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 38.

Later studies that cite this one

43 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Genetics from nearby years

Also tagged “r47h”

363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Genetics

See all studies in Genetics →